SCHOTT Pharma KGaA Past Earnings Performance
Past criteria checks 2/6
SCHOTT Pharma KGaA has been growing earnings at an average annual rate of 15.4%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 11.9% per year. SCHOTT Pharma KGaA's return on equity is 19.6%, and it has net margins of 15.9%.
Key information
15.4%
Earnings growth rate
15.4%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 11.9% |
| Return on equity | 19.6% |
| Net Margin | 15.9% |
| Next Earnings Update | 12 Dec 2024 |
Recent past performance updates
Recent updates
SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) Business Is Trailing The Market But Its Shares Aren't
Oct 27
SCHOTT Pharma AG & Co. KGaA Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Sep 01Is There An Opportunity With SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) 31% Undervaluation?
Aug 07Earnings Miss: SCHOTT Pharma AG & Co. KGaA Missed EPS By 18% And Analysts Are Revising Their Forecasts
Jul 01We Think SCHOTT Pharma KGaA (ETR:1SXP) Can Stay On Top Of Its Debt
Jun 07Calculating The Intrinsic Value Of SCHOTT Pharma AG & Co. KGaA (ETR:1SXP)
Mar 28Revenue & Expenses Breakdown
How SCHOTT Pharma KGaA makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 949 | 150 | 126 | 27 |
| 31 Mar 24 | 916 | 135 | 125 | 28 |
| 31 Dec 23 | 906 | 158 | 124 | 27 |
| 30 Sep 23 | 899 | 152 | 123 | 27 |
| 30 Jun 23 | 873 | 143 | 123 | 24 |
| 30 Sep 22 | 821 | 125 | 111 | 24 |
| 30 Sep 21 | 649 | 101 | 92 | 22 |
| 30 Sep 20 | 584 | 77 | 90 | 24 |
Quality Earnings: 1SXP has high quality earnings.
Growing Profit Margin: 1SXP's current net profit margins (15.9%) are lower than last year (16.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1SXP's earnings have grown by 15.4% per year over the past 5 years.
Accelerating Growth: 1SXP's earnings growth over the past year (5.4%) is below its 5-year average (15.4% per year).
Earnings vs Industry: 1SXP earnings growth over the past year (5.4%) did not outperform the Life Sciences industry 5.4%.
Return on Equity
High ROE: 1SXP's Return on Equity (19.6%) is considered low.